Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)

References

• AbadessoCAlmeidaHIVirellaD2004Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unitJ Hosp Infect58384115350712
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn2003Policy statement: revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infectionsPediatrics1121442614654627
   PubMed Web of Science ®Google Scholar
• ArnoldSRWangEELawBJ1999Variable morbidity of respiratory syncytial virus Infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in CanadaPediatr Infect Dis J18866910530581
   PubMed Web of Science ®Google Scholar
• BalaPRyanCAMurphyBP2005Hospital admissions for bronchiolitis in preterm infants in the absence of respiratory syncytial virus prophylaxisArch Dis Child Fetal Neonatal Ed9092
   Web of Science ®Google Scholar
• BoeckhMBerreyMMBowdenRA2001Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplantsJ Infect Dis184350411443562
   PubMed Web of Science ®Google Scholar
• BoyceTGMellenBGMitchelEF2000Rates of hospitalization for respiratory syncytial virus infection among children in MedicaidJ Pediatr1378657011113845
   PubMed Web of Science ®Google Scholar
• BroughtonSRobertsAFoxG2005Prospective study of healthcare utilization and respiratory morbidity due to RSV infection in prematurely born infantsThorax6010394416227330
   PubMed Web of Science ®Google Scholar
• Carbonell-EstranyXQueroJBustosG2000Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective studyPediatr Infect Dis J19592710917214
   PubMed Web of Science ®Google Scholar
• Carbonell-EstranyXQueroJthe IRIS Study Group2001RSV hospitalization rates in premature infants born over two consecutive seasonsPediatr Infect Dis J20874911734767
   PubMed Web of Science ®Google Scholar
• CastroCArnoldJJCameronCE2005Incorporation fidelity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspectiveVirus Res107141915649560
   PubMed Web of Science ®Google Scholar
• ChinJMagoffinRLShearerLA1969Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric populationAm J Epidemiol89449634305200
   PubMed Web of Science ®Google Scholar
• CillaGSarasuaAMontesM2006Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, SpainEpidemiol Infect1345061316638164
   PubMed Web of Science ®Google Scholar
• ClarkSJBeresfordMWSubhedarNV2000Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohortArch Dis Child83313610999865
   PubMed Web of Science ®Google Scholar
• CohenASorrentinoMPowersT2000Key findings after a second season of use: effectiveness of palivizumab for preventing serious RSV diseaseJ Respir Dis Pediatr2S302
   Google Scholar
• CohenAHBoronMLDingivanC2005A phase IV study of the safety of Synagis® (palivizumab) for prophylaxis of respiratory syncytial virus disease in children with – cystic fibrosis [abstract]American Thoracic Society Abstracts, 2005 International Conference2A178
   Google Scholar
• Committee on Infectious Diseases and Committee on Fetus and Newborn2003Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infectionsPediatrics11211426
   Google Scholar
• Community-acquired respiratory viruses2004Am J Transplant4Suppl 1010510915504224
   PubMedGoogle Scholar
• CoxRARaoPBrandon-CoxC2001The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unitJ Hosp Infect481869211439005
   PubMed Web of Science ®Google Scholar
• DeVincenzoJPAitkenJHarrisonL2003Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibodyJ Pediatr143123612915838
   PubMed Web of Science ®Google Scholar
• DeVincenzoJP2004Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral loadPediatr Res56914715470202
   PubMed Web of Science ®Google Scholar
• DeVincenzoJPHallCBKimberlinDW2004Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutantsJ Infect Dis190975815295704
   PubMed Web of Science ®Google Scholar
• DeshpandeSANorthernV2003The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical areaArch Dis Child881065914670770
   PubMed Web of Science ®Google Scholar
• DuppenthalerAGorgievski-HrisohoMFreyU2003Two-year periodicity of respiratory syncytial virus epidemics in SwitzerlandInfection31758012682811
   PubMed Web of Science ®Google Scholar
• DuppenthalerAAmmannRAGorgievski-HrisohoM2004Low incidence of respiratory syncytial virus hospitalizations in haemo-dynamically significant congenital heart diseaseArch Dis Child89961515383442
   PubMed Web of Science ®Google Scholar
• ElhassanNOSorberoMESHallCB2006Cost-effectiveness analysis of palivizumab in premature infants without chronic lung diseaseArch Pediatr Adolesc Med1601070617018467
   PubMed Web of Science ®Google Scholar
• EmbletonNDHarkenseeCMckeanMC2005Palivizumab for preterm infants. Is it worth itArch Dis Child Fetal Neonatal Ed902869
   PubMed Web of Science ®Google Scholar
• FeltesTFCabalkaAKMeissnerC2003Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseJ Pediatr1435324014571236
   PubMed Web of Science ®Google Scholar
• Figueras-AloyJCarbonell-EstranyXQueroJfor the IRIS study group2004Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in SpainPediatr Infect Dis J238152015361718
   PubMed Web of Science ®Google Scholar
• FjaerliHOFarstadTBratlidD2004Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993–2000 a population-based retrospective studyBMC Pediatrics42515606912
   PubMedGoogle Scholar
• FulginitiVAEllerJJSieberOF1969Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccineAm J Epidemiol89435484305199
   PubMed Web of Science ®Google Scholar
• GeskeyJMCenevivaGDBrummelG2004Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefitClin Ther262130715823776
   PubMed Web of Science ®Google Scholar
• GolombekSGBerningFLagammaEF2004Compliance with prophylaxis for respiratory syncytial virus infection in a home settingPediatr Infect Dis J233182215071285
   PubMed Web of Science ®Google Scholar
• GreenoughACoxSAlexanderJ2001Health care utilization of infants with chronic lung disease, related to hospitalization for RSV infectionArch Dis Child85463811719328
   PubMed Web of Science ®Google Scholar
• GrimaldiMGouyonBMichautF2004Epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasiaPediatr Infect Dis J231081515626942
   PubMed Web of Science ®Google Scholar
• GrimaldiMGouyonBSagotP2007Palivizumab efficacy in preterm infants with gestational age ≤30 weeks without bronchopulmonary dysplasiaPediatr Pulmonol421899217243184
   PubMed Web of Science ®Google Scholar
• GroothuisJR2001Safety and tolerance of palivizumab administration in a large northern hemisphere trialPediatr Infect Dis J206283011419509
   PubMed Web of Science ®Google Scholar
• GroothuisJRSimoesEALevinMJ1993Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study GroupN Engl J Med3291524308413475
   PubMed Web of Science ®Google Scholar
• HallCBPowellKRMacDonaldNE1986Respiratory syncytial viral infection in children with compromised immune functionN Engl J Med31577813724802
   PubMed Web of Science ®Google Scholar
• HallCBWalshEESchnabelKC1990Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory childrenJ Infect Dis1621283902230258
   PubMed Web of Science ®Google Scholar
• HallCB2001Respiratory syncytial virus and parainfluenza virusN Engl J Med34419172811419430
   PubMed Web of Science ®Google Scholar
• HenckelELuthanderJBerggrenE2004Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002Pediatr Infect Dis J23273114743042
   PubMed Web of Science ®Google Scholar
• HeikkinenTValkonenHLehtonenL2005Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxisArch Dis Child Fetal Neonatal Ed90F64815613580
   PubMed Web of Science ®Google Scholar
• HendersonJHilliardTNSherriffA2005Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort studyPediatr Allergy Immunoc1638692
   PubMed Web of Science ®Google Scholar
• HiattPWGraceSCKozinetzCA1999Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosisPediatrics1036192610049966
   PubMed Web of Science ®Google Scholar
• HillSRMitchellASHenryDA2000Problems with interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits SchemeJAMA28321162110791503
   PubMed Web of Science ®Google Scholar
• HolmanRCCurnsATCheekJE2004Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general Unites States infant populationPediatrics11443744
   PubMed Web of Science ®Google Scholar
• Impact-RSV Study Group1998Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infantsPediatrics1025317
   Web of Science ®Google Scholar
• IwaneMKEdwardsKMSzilagyiPG2004Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young childrenPediatrics11317586415173503
   PubMed Web of Science ®Google Scholar
• JoffeSEscobarGJBlackSB1999Rehospitalization for respiratory syncytial virus among premature infantsPediatrics1048949910506231
   PubMed Web of Science ®Google Scholar
• JohnsonSOliverCPrinceGA1997Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virusJ Infect Dis1761215249359721
   PubMed Web of Science ®Google Scholar
• Kamal-BahlSDoshiJCampbellJ2002Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic reviewArch Pediatr Adolesc Med15610344112361451
   PubMed Web of Science ®Google Scholar
• KilaniMMMohammedKANasreenN2004Respiratory syncytial virus causes increased bronchial epithelial permeabilityChest1261869115249461
   PubMed Web of Science ®Google Scholar
• KorppiMPiippo-SavolainenEKorhonenK2004Respiratory morbidity 20 years after RSV infection in infancyPediatr Pulmonol381556015211700
   PubMed Web of Science ®Google Scholar
• KuselMMHde KlerkNHHoltPG2006Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life: a birth cohort studyPediatr Infect Dis J25680616874165
   PubMed Web of Science ®Google Scholar
• KusudaSKoizumiTSakaiT2006Results of clinical surveillance during the Japanese first palivizumab season in 2002–2003Pediatr Int48362816911080
   PubMed Web of Science ®Google Scholar
• Lacaze-MasmonteilTRozéJ-CFaurouxB2002Incidence of Respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with palivizumab as RSV prophylaxisPediatr Pulmonol34181812203846
   PubMed Web of Science ®Google Scholar
• Lacaze-MasmonteilTSeidenbergJMitchellI2003Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infectionDrug Saf262839112608889
   PubMed Web of Science ®Google Scholar
• Lacaze-MasmonteilTTruffertPPinquierD2004Lower respiratory tract illness and RSV prophylaxis in very premature infantsArch Dis Child89562715155404
   PubMed Web of Science ®Google Scholar
• LawBJLangleyJMAllenU2004The pediatric investigators collaborative network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestationPediatr Infect Dis J238061415361717
   PubMed Web of Science ®Google Scholar
• LeaderSKohlhaseK2003Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000J Pediatr143SupplS1273214615711
   PubMed Web of Science ®Google Scholar
• LeclairJMFreemanJSullivanBF1987Prevention of nosocomial respiratory syncytial infections through compliance with glove and gown isolation precautionsN Engl J Med317329343600729
   PubMed Web of Science ®Google Scholar
• LieseJGGrillEFischerB2003Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in GermanyEur J Pediatr162230612647195
   PubMed Web of Science ®Google Scholar
• Little-van den HurkSDMapletoftJWArsicN2007Immunopathology of RSV infection: prospects for developing vaccines without developing this complicationRev Med Virol1753417004293
   PubMed Web of Science ®Google Scholar
• MacartneyKKGorelickMHManningML2000Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection controlPediatrics106520610969097
   PubMed Web of Science ®Google Scholar
• McBrideSCChiangVWGoldmannDA2005Preventable adverse events in infants hospitalized with bronchiolitisPediatrics116603816140699
   PubMed Web of Science ®Google Scholar
• McCormickJTubmanR2002Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unitPediatr Pulmonol34262612205567
   PubMed Web of Science ®Google Scholar
• McCormickJSouthernKW2007A survey of palivizumab for infants with cystic fibrosis in the UKArch Dis Child9287817185451
   PubMed Web of Science ®Google Scholar
• MadgePPatonJYMcCollJH1992Prospective controlled study of four infection-control procedures to prevent nosocomial infection with respiratory syncytial virusLancet3401079831357462
   PubMed Web of Science ®Google Scholar
• MalleyRDeVincenzoJRamiloO1998Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F proteinJ Infect Dis1781555619815203
   PubMed Web of Science ®Google Scholar
• MebergABruuAL2006Respiratory syncytial virus infections in congenital heart defects – hospitalizations and costsActa Paediatr95404616720485
   PubMed Web of Science ®Google Scholar
• MeissnerHCLongSLthe Committee on Infectious Diseases and Committee on Fetus and Newborn2003Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infectionsPediatrics11214475214654628
   PubMed Web of Science ®Google Scholar
• MejíasAChávez-BuenoSRíosAM2004Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV modelAntimicrob Agents Chemother4818112215105140
   PubMed Web of Science ®Google Scholar
• MejíasAChávez-BuenoSRíosAM2005Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potencyAntimicrob Agents Chemother494700716251314
   PubMed Web of Science ®Google Scholar
• MitchellIToughSGillisL2006Beyond randomized controlled trials: a “real life” experience of respiratory syncytial virus infection prevention in infancy with and without palivizumabPediatr Pulmonol4111677417058279
   PubMed Web of Science ®Google Scholar
• MohanAKBraunMMEllenbergS2004Deaths among children less than two years of age receiving palivizumab: an analysis of comorbiditiesPediatr Infect Dis J23342515071290
   PubMed Web of Science ®Google Scholar
• MooreTJWeissSRKaplanS2002Reported adverse drug events in infants and children under 2 years of agePediatrics110e5312415059
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics2001Table 46. Live births, infant deaths, and infant mortality rates by plurality, birthweight, race of mother, and gestational age: United States, 2001 period data [online]Accessed 2 February 2007 URL: http://www.cdc.gov/nchs/data/dvs/LINK01WK46.pdf
   Google Scholar
• NavérLErikssonMEwaldU2004Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in SwedenActa Paediatr931470315513574
   PubMed Web of Science ®Google Scholar
• NullDPollaraBDennehyPH2005Safety and immunogenicity of palivizumab (Synagis) administered for two seasonsPediatr Infect Dis J241021316282947
   PubMed Web of Science ®Google Scholar
• NumaA2000Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxisJ Paediatr Child Health36422711036794
   PubMed Web of Science ®Google Scholar
• OhPILanctôtKLYoonA2002Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomesPediatr Infect Dis J21512812182374
   PubMed Web of Science ®Google Scholar
• OttoliniMGCurtisSRMathewsA2002Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal modelBone Marrow Transplant291172011850705
   PubMed Web of Science ®Google Scholar
• Palivizumab Outcomes Registry Study Group2003Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001 results from the palivizumab outcomes registryPediatr Pulmonol35484912746948
   PubMed Web of Science ®Google Scholar
• PedrazCCarbonell-EstranyXFigueras-AloyJ2003Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infantsPediatr Infect Dis J22823714506376
   PubMed Web of Science ®Google Scholar
• PraisDDaninoDSchonfeldT2005Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national surveyChest12827657116236953
   PubMed Web of Science ®Google Scholar
• PurcellKFergieJ2004Risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002Pediatr Infect Dis J234182315131464
   PubMed Web of Science ®Google Scholar
• ReschBGusenleitnerWMullerWDHaasJ2006Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeksEur J Clin Microbiol Infect Dis25120216491302
   PubMed Web of Science ®Google Scholar
• RobbinsJMTilfordJMGillaspySR2002Parental emotional and time costs predict compliance with respiratory syncytial virus prophylaxisAmbul Pediatr2444812437390
   PubMedGoogle Scholar
• RomeroJR2003Palivizumab prophylaxis of respiratory syncytial virus disease from 1998–2002 results from four years of palivizumab usagePediatr Infect Dis J22S465412671452
   PubMed Web of Science ®Google Scholar
• Sáez-LllorensXCastanoENullD1998Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasiaPediatr Infect Dis J17787919779762
   PubMed Web of Science ®Google Scholar
• Sáez-LlorensXMorenoMTRamiloO2004Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virusPediatr Infect Dis J237071215295219
   PubMed Web of Science ®Google Scholar
• SajiTNakazawaMHaradaK2005Safety and efficacy of palivizumab prophylaxis in children with congenital heart diseasePediatr Int4739740316091076
   PubMed Web of Science ®Google Scholar
• ShiremanTIBramanKS2002Impact and cost-effectiveness of RSV prophylaxis for Kansas Medicaid’s high-risk childrenArch Pediatr Adolesc Med1561251512444839
   PubMed Web of Science ®Google Scholar
• SigursNBjarnasonRSigurbergssonF2000Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7Am J Respir Crit Care Med1611501710806145
   PubMed Web of Science ®Google Scholar
• SigursNGustafssonPMBjarnasonR2005Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13Am J Respir Crit Care Med1711374115516534
   PubMed Web of Science ®Google Scholar
• SimoesEAFSondheimerHMTopFHJrRespiratory syncytial virus immuneglobulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart diseaseJ Pediatr133492999787686
   PubMed Web of Science ®Google Scholar
• SimpsonSBurlsAA systematic review of the effectiveness and cost-effectiveness of palivizumab (Synagis) in the prevention of respiratory syncytial virus (RSV) infection infection in infants at high risk of infectionBirmingham UKDepartment of Public Health and Epidemiology, University of Birmingham2001
   Google Scholar
• SingletonRDooleyLBrudenD2003Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infantsPediatr Infect Dis J22540512799511
   PubMed Web of Science ®Google Scholar
• SorrentinoMPowersTThe Palivizumab Outcomes Study Group2000Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus seasonPediatr Infect Dis J1910687111099087
   PubMed Web of Science ®Google Scholar
• SteinRTSherrillDMorganWJRespiratory syncytial virus in early life and risk of wheeze and allergy by age 13 yearsLancet354541510470697
   PubMed Web of Science ®Google Scholar
• StevensTPSinkinRAHallCB2000Respiratory syncytial virus and premature infants born at 32 weeks’ gestation or earlierArch Pediatr Adolesc Med154556110632251
   PubMed Web of Science ®Google Scholar
• Subcommittee on Diagnosis and Management of Bronchiolitis2006Diagnosis and management of bronchiolitisPediatrics11817749317015575
   PubMed Web of Science ®Google Scholar
• SubramanianSWeismanLRhodesT1998Safety, tolerance and pharmacokinetics of humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasiaPediatr Infect Dis J1711059493805
   PubMed Web of Science ®Google Scholar
• Swedish Consensus Group2001Management of infections caused by respiratory syncytial virusScand J Infect Dis33323811440215
   PubMedGoogle Scholar
• Terletskaia-LadwigEndersGiselaSchalastaGEndersM2005Defining the timing of respiratory syncytial virus (RSV) outbreaks: an epidemiological studyBMC Infect Dis52015801975
   PubMed Web of Science ®Google Scholar
• The Impact-RSV Study Group1998Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infantsPediatrics1025317
   PubMed Web of Science ®Google Scholar
• The PREVENT Study Group1997Reduction of RSV hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxisPediatrics999398989345
   PubMed Web of Science ®Google Scholar
• ThomasNJHollenbeakCSCenevivaGD2007Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis modelJ Pediatr Hematol Oncol292273217414564
   PubMed Web of Science ®Google Scholar
• ThompsonWWShayDKWeintraubE2003Mortality associated with influenza and respiratory syncytial virus in the United StatesJAMA2891798612517228
   PubMed Web of Science ®Google Scholar
• VogelAMLennonDRBroadbentR2002Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infantsJ Paediatr Child Health38550412410864
   PubMed Web of Science ®Google Scholar
• WangEELLawBJStephensD1995Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infectionJ Pediatr12621297844667
   PubMed Web of Science ®Google Scholar
• WeiglJAIPuppeWSchmittHJ2001Incidence of respiratory syncytial virus-positive hospitalizations in GermanyEur J Clin Microbiol Infect Dis20452911561800
   PubMed Web of Science ®Google Scholar
• WillsonDFLandriganCPHornSD2003Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumoniaJ Pediatr143S142914615713
   PubMed Web of Science ®Google Scholar
• WinchesterLGarcíaLGarcíaIConcepciónCB2002Prevention of respiratory syncytial virus infection among Puerto Rican infantsP R Health Sci J21191312243108
   PubMedGoogle Scholar
• WolfDGGreenbergDKalksteinD2006Comparison of human metapneumovirus, respiratory syncytial virus and influenza A virus lower respiratory tract infections in hospitalized young childrenPediatr Infect Dis J25320416567983
   PubMed Web of Science ®Google Scholar
• WuSYBonaparteJPyatiS2004Palivizumab use in very premature infants in the neonatal intensive care unitPediatrics114e554615520088
   PubMed Web of Science ®Google Scholar
• YountLEMahleWT2004Economic analysis of palivizumab in infants with congenital heart diseasePediatrics11416061115574622
   PubMed Web of Science ®Google Scholar
• ZhaoXChenFPSullenderWM2004Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton ratsVirology3186081214972528
   PubMed Web of Science ®Google Scholar